Improvement of chronic osteomyelitis after granulocyte colony stimulating factor
- PMID: 24426334
- PMCID: PMC3572250
- DOI: 10.1007/s12288-011-0127-6
Improvement of chronic osteomyelitis after granulocyte colony stimulating factor
Abstract
Background: chronic osteomyelitis represents a persistent bone and bone marrow infection easy to diagnose in the presence of pain, erythema, swelling, and a draining sinus but more difficult to detect in the absence of the preceding features and with a painful orthopaedic prosthesis.
Case description: we report upon an elderly gentleman with myelodysplasia requiring revision surgery for a fractured prosthetic left knee. He had clinical, laboratory, and radiological features of chronic osteomyelitis that improved only with administration of granulocyte colony stimulating factor (G-CSF).
Literature review: G-CSF has been successfully employed to treat resistant osteomyelitis in three young patients with primary defects of monocyte and neutrophil killing. A randomized trial confirmed the efficacy of G-CSF in the treatment of chronic osteomyelitis in twenty patients with diabetic foot ulcers and a rat model confirmed the efficacy of G-CSF in acute osteomyelitis.
Clinical relevance: our case highlights the usefulness of G-CSF treatment for immune suppressed patients with resistant chronic osteomyelitis.
Figures



Similar articles
-
Granulocyte-colony stimulating factor administration for neurological improvement in patients with postrehabilitation chronic incomplete traumatic spinal cord injuries: a double-blind randomized controlled clinical trial.J Neurosurg Spine. 2018 Jul;29(1):97-107. doi: 10.3171/2017.11.SPINE17769. Epub 2018 Apr 27. J Neurosurg Spine. 2018. PMID: 29701561 Clinical Trial.
-
Diagnosis and treatment of diabetic foot infections.Plast Reconstr Surg. 2006 Jun;117(7 Suppl):212S-238S. doi: 10.1097/01.prs.0000222737.09322.77. Plast Reconstr Surg. 2006. PMID: 16799390
-
Randomised placebo-controlled trial of granulocyte-colony stimulating factor in diabetic foot infection.Lancet. 1997 Sep 20;350(9081):855-9. doi: 10.1016/S0140-6736(97)04495-4. Lancet. 1997. PMID: 9310604 Clinical Trial.
-
Recombinant granulocyte-macrophage colony-stimulating factor (rGM-CSF). A review of its pharmacological properties and prospective role in the management of myelosuppression.Drugs. 1992 Apr;43(4):516-60. doi: 10.2165/00003495-199243040-00008. Drugs. 1992. PMID: 1377118 Review.
-
Granulocyte-colony stimulating factor therapy to induce neovascularization in ischemic heart disease.Dan Med J. 2012 Mar;59(3):B4411. Dan Med J. 2012. PMID: 22381094 Review.
References
-
- Carulli G. Effects of recombinant human granulocyte colony-stimulating factors administration on neutrophil phenotype and functions. Haematologica. 1997;82:606–616. - PubMed
-
- de Lalla F, Pellizzer G, Strazzabosco M, Martini Z, Du Jardin G, Lora L, Fabris P, Benedetti P, Erle G. Randomized prospective controlled trial of recombinant granulocyte colony-stimulating factor as adjunctive therapy for limb-threatening diabetic foot infection. Antimicrob Agents Chemother. 2001;45:1094–1098. doi: 10.1128/AAC.45.4.1094-1098.2001. - DOI - PMC - PubMed
Publication types
LinkOut - more resources
Full Text Sources